<DOC>
	<DOCNO>NCT00944918</DOCNO>
	<brief_summary>A partially-blind , randomise , multicentre phase III trial Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane postmenopausal locally advance / metastatic breast cancer patient progress NSAIs . Randomisation Faslodex ± Arimidex / Arimidex-Placebo exemestane open ( 1:1:1 ) . For Faslodex treat patient randomisation Arimidex Arimidex-Placebo double-blind .</brief_summary>
	<brief_title>Study Faslodex With Without Concomitant Arimidex Versus Exemestane Following Progression Non-steroidal Aromatase Inhibitors ( NSAI )</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast . Metastatic disease must measurable evaluable Relapsed progressed prior treatment singleagent NSAI , meet either follow criterion : NSAI give adjuvant therapy last ≥ 12 month OR Achieved objective CR , PR , SD last ≥ 6 month prior 1stline Female postmenopausal patient Hormone receptor status1 . ER PgR NK2 . ERve PgR ve3 . ER NK Prescribed Tamoxifen metastatic disease Rapidly progressive visceral disease Patients malignancies within last 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>